CYTK Stock Analysis: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$76.84
-0.34 (-0.44%)
▼
5d:
+3.66%
30d:
-6.2%
90d:
-1.56%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 7, 2026 at $76.76 · last confirmed Aug 17, 2026
Strength: 8.9/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $76.84, which is considered slightly low relative to its 30-day fair value range of $76.21 to $81.21.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is approaching resistance at $78.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYTK scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $109.90 (+43.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is approaching resistance at $78.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYTK scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $109.90 (+43.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$76.21 -
$81.21
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.0% below Wall St target ($109.90)
- BULLISH: Bottoming setup score 67/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$76.21 -
$81.21
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$72.12
Resistance Level
$78.95
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.26
Wall Street Target
$109.90
(+43.0%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: August 22, 2026 2:11 PM ET
Data refreshes hourly during market hours. Next update: 3:11 PM
Data refreshes hourly during market hours. Next update: 3:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Fady Ibraham Malik
SELL
3500 shares
2026-04-21
Robert I Blum
SELL
7500 shares
2026-04-15
Andrew Callos
SELL
7449 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
